What are "the built in costs of the shorts". This should be good. I've shorted many times. No costs at all other than dividends. If a company is hard to borrow, theoretically there could be a cost. ENTR isn't hard to borrow though. Call up your broker if you don't believe me.
You simply have no idea what you're talking about.
And there's no evidence that the share price is falling "due to shorts". There's low short interest in this stock.
They filed the presentation that they will be given. Here is some info from it:
-expect new products to outpace decline in mature products
-focus on profitable growth
-continued product development
-expanding sales channels and marketing
Cash and Cash Equivalents - In 2012, $11.4M, in 2013, $5.2M
Total assets - In 2012, $32.6M, in 2013, $29.4M.
So, although their cash has dropped a little more than in half, their total assets still look good.
So, will they try to sell more shares? At first, I thought they might, but I'm not so sure about that now.
They have NO debt outstanding.
In the last 2 years, they have released 12 new products.
One of them is the xPico Wi-Fi. They give an example of how it can be used in A/C units.
xPico Wi-Fi: Mobile Management of Heating System --enamble technician to use a tablet to securely access the heating and cooling system without having access to the customer's network. this enabled the technician to access, review, manage, and control the heating & cooling system controls -- adjust temperature levels, order additional fuel, provide real-time service.
Although this is nice, what they really need to add to the ability to contact xPico through someone's Wi-Fi network securely. Everyone has Wi-Fi now-a-days so to save a service call, they can get data through Wi-Fi. Now, this may sound similar to AccessMyDevice, BUT don't make it a pay service and don't make it as complicated. What if a furnace company could tell days before the furnace breaks that it can happen by receiving an SOS transmission from it? Wouldn't this be an added feature that would be in high demand? Wouldn't everyone want this feature on their new furnace unit?
Lastly, I must say, marketing has improved by the release of all those product case studies that are emailed to everyone on their email list. THOUGH, they need to add these case studies to the websites. AND they should go a step further and do online presentations.
sorry have-anger, i'm not leaving. this company is a financial failure and you're gonna lose another 75% in the coming quarter as Johnson floats a massive secondary to avoid an auditor's "going concern" warning... which would happen at year-end because liquid cash would be less than 3-months of operating capital. EU approval and bogus upgrades from tiny brokers won't save this stock. the best business decision for Johnson would be to file bankruptcy in the next quarter, so he can save his job and at least keep provenge on the market for 2014. whatever he does, common shareholders will lose big.
Last time Mark spoke at a non earnings event the stock dropped after he spoke. It stayed within right around 27 for over a week. That was when home was announced. I don't know where you are coming up with 10%. Home was announced April 4th check out the price history and you will see there certainly was not a 10% rise.
you're in the same situation as Kel,, barf,, Tex...spandex & all the REST......you're just MAN enough to admit it
For Novavax, I can see Matrix-M use in every of its candidates.
As far as Genocea and HSV, their "vaccine" is pretty useless without Matrix-M, which leads me to think if Novavax could just develop one themselves. If they don't, then Genocea is at the mercy of Novavax because their vaccine does not work without Matrix-M.
And as I said before, Crucell is testing Matrix-M, and I would be surprised one bit if JNJ (parent of Crucell) decides to make a bid for Novavax from nowhere.
I would really like to see any oncology vaccine tested tested with Matrix-M by another company, if we can get our foot in that door...look out, every large pharma is moving towards cancer treatments. And there is such a high reject rate, if Matrix-M could help there...it would be a game-changer...and Novavax AB will becomes more valuable than Novavax. LOL.